World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
39536
World Ranking
14853
National Ranking
7511

Overview

Richard R. Furman is affiliated with NewYork-Presbyterian Hospital in the United States and has contributed extensively to research in the field of medicine, particularly focusing on chronic lymphocytic leukemia (CLL) and related hematological conditions. Their scholarly output spans genetics, pathology and forensic medicine, oncology, molecular biology, and immunology.

Furman's research primarily addresses topics including chronic lymphocytic leukemia research, lymphoma diagnosis and treatment, immunodeficiency and autoimmune disorders, chronic myeloid leukemia treatments, CAR-T cell therapy research, monoclonal and polyclonal antibodies research, and advanced breast cancer therapies.

Frequent publication venues for Furman include Blood, the Journal of Clinical Oncology, Haematologica, Blood Advances, and Clinical Lymphoma Myeloma & Leukemia. They have a significant presence in Blood with 29 publications and also maintain consistent contributions in other key journals focused on oncology and hematology.

Among their recent papers are:

  • Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial, 2021, Journal of Clinical Oncology
  • Outcomes of COVID-19 in Patients with CLL: A Multicenter International Experience, 2020, Blood
  • Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study, 2020, Clinical Cancer Research
  • Detailed Safety Profile of Acalabrutinib vs Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia in the ELEVATE-RR Trial, 2023, Blood
  • Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia, 2021, Blood

Furman collaborates frequently with other researchers, with prominent coauthors including Jennifer R. Brown, John N. Allan, John C. Byrd, Paolo Ghia, and Peter Hillmen, with collaboration counts ranging from 16 to 25 joint works.

Best Publications

  • Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Ian W. Flinn

  • Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

    Richard R. Furman;Jeff P. Sharman;Steven E. Coutre;Bruce D. Cheson

  • Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

    J. C. Byrd;J. R. Brown;Susan O'Brien;J. C. Barrientos

  • Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

    C.M. Legendre;C. Licht;P. Muus;L.A. Greenbaum

  • Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

    Ranjana H. Advani;Joseph J. Buggy;Jeff P. Sharman;Sonali M. Smith

  • Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

    Jennifer A. Woyach;Richard R. Furman;Ta Ming Liu;Hatice Gulcin Ozer

  • Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

    Kenneth R. Carson;Andrew M. Evens;Elizabeth A. Richey;Thomas M. Habermann

  • Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Bonnie Harrington;Susan O'Brien;Jeffrey A. Jones

  • Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

    Jason A. Dubovsky;Kyle A. Beckwith;Gayathri Natarajan;Jennifer A. Woyach

  • Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Jan A. Burger

  • Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

    William G. Wierda;Thomas J. Kipps;Jiří Mayer;Stephan Stilgenbauer

  • Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

    Jennifer R. Brown;John C. Byrd;Steven E. Coutre;Don M. Benson

  • Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

    Owen A. O'Connor;Barbara Pro;Lauren Pinter-Brown;Nancy Bartlett

  • Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

    Susan O'Brien;Richard R Furman;Steven E Coutre;Jeff P Sharman

  • Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3′ Splice Site Selection through Use of a Different Branch Point

    Rachel B. Darman;Michael Seiler;Anant A. Agrawal;Kian H. Lim

  • Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies

    Christoph Licht;Larry A. Greenbaum;Petra Muus;Sunil Babu

  • Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma

    Peter Martin;Amy Chadburn;Paul Christos;Karen Weil

  • Single-Agent Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia: A 5-Year Experience

    Susan O'Brien;Susan O'Brien;Richard R. Furman;Steven Coutre;Ian W. Flinn

  • Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

    Jia Ruan;Peter Martin;Richard R. Furman;Shing M. Lee

  • Modulation of NF-κB Activity and Apoptosis in Chronic Lymphocytic Leukemia B Cells

    Richard R. Furman;Zahra Asgary;John O. Mascarenhas;Hsiou-Chi Liou

Frequent Co-Authors

John P. Leonard
John P. Leonard Cornell University
John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute
Steven Coutre
Steven Coutre Stanford University
Morton Coleman
Morton Coleman Cornell University
Susan O'Brien
Susan O'Brien University of California, Irvine
Peter Hillmen
Peter Hillmen St James's University Hospital
Jennifer R. Brown
Jennifer R. Brown Harvard University
Ian W. Flinn
Ian W. Flinn Sarah Cannon Research Institute
William G. Wierda
William G. Wierda The University of Texas MD Anderson Cancer Center
Thomas J. Kipps
Thomas J. Kipps University of California, San Diego

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in exploring alternative or complementary paths within healthcare, there are several related online degree and certification programs to consider. For those pursuing nursing, there are online bsn programs for non nurses that provide a flexible route to becoming a Registered Nurse, especially for individuals with a non-nursing background.

Not everyone needs to take traditional entrance exams to start their nursing journey. Some students may prefer a nursing school that doesn't require teas, removing a common barrier to entry and streamlining the admission process.

For those interested in non-clinical roles, healthcare administration offers a strong career outlook. Many schools now offer an online healthcare administration degree, ideal for aspiring leaders aiming to manage healthcare organizations.

Another rapidly growing healthcare field is medical billing and coding. Accredited medical billing and coding schools online help students gain necessary skills for essential back-office roles, often with financial aid options.

Best Scientists Citing Richard R. Furman

Trending Scientists